Fig. 7: Adoptive transfer of macrophages primed with Gpr37 activators confers protection against malaria and listeria infection.

a Experimental design to test whether adoptive transfer of pMΦ primed with Gpr37 activators can attenuate malaria infection. WT or Gpr37^−/− pMΦ were primed with vehicle, ARU (30 μM), or NPD1 (30 nM) for 24 h, followed by washout of the drug and adoptive transfer of pMΦ (5 × 10^4, I.P.) into P.b.-inoculated Gpr37^−/− mice (1 × 10⁴ sporozoites, I.V.) 2 d after infection. b Survival curves of Gpr37^−/− mice treated with vehicle-, ARU-, or NPD1-primed WT pMΦ. As a control, Gpr37^−/− mice were also treated with ARU-primed pMΦ from Gpr37^−/− mice. Sample sizes are indicated in brackets. c, d Flow cytometry analysis of peripheral blood samples taken from the mice outlined in a 10 d after P.b. inoculation. Infected RBCs (iRBCs) were detected using Hoechst dye (1 μg/ml) and negative for NO dye (650/670). c Representative images of flow cytometry reveal the proportion of iRBCs (Hoechst⁺/NOS⁻) in each treatment group (see gating strategy in supplementary Fig. 4d). d Quantification of iRBCs in each group (10⁶ RBCs analyzed per sample), n = 6–9 mice/group as indicated. e Experimental design for adoptive transfer of WT or Gpr37^−/− pMΦ primed with vehicle or NPD1 (30 nM) for 24 h administered 6 h after inoculation of Gpr37^−/− mice with L.m. (1 × 10⁷, I.P.). f Survival curves of Gpr37^−/− mice treated with WT or Gpr37^−/− pMΦ primed with vehicle or NPD1. Sample sizes are indicated in the brackets. g Time course of rectal temperature 0 h, 6 h, or 24 h after L.m. inoculation. Sample sizes are indicated in the brackets. Data are expressed as the mean ± s.e.m. and statistically analyzed by Mantel–Cox test (b, f), One-way ANOVA followed by Tukey’s post-hoc test (d), or Two-way ANOVA followed by Tukey’s (g).